Dan Brody, MD
Allergy & Immunology · Washington, DCNPI 1376606624
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 402 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 29.3% of the total. 2025 is the largest year on record at $2,636, 2.0 times the $1,290 reported in 2020.
Across 402 payments — averaging $23.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Sanofi$1K
- GSK$1K
- Novartis$624
- Regeneron Healthcare Solutions, Inc.$414
- Genentech USA, Inc.$412
- plus $3K from 23 others
What the payments were for
- Food & beverage$9,287100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 116 | $2,724 |
| Sanofi | 51 | $1,300 |
| GSK | 52 | $1,074 |
| Novartis | 27 | $624 |
| Regeneron Healthcare Solutions, Inc. | 17 | $414 |
| Genentech USA, Inc. | 16 | $412 |
| Pfizer | 20 | $393 |
| Optinose US, Inc. | 19 | $355 |
| Amgen | 11 | $331 |
| Kaleo, Inc. | 12 | $269 |
| Grifols USA, LLC | 8 | $220 |
| Boehringer Ingelheim | 11 | $206 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $172 |
| Hikma Pharmaceuticals USA | 7 | $134 |
| Incyte Corporation | 5 | $115 |
| Medtronic | 3 | $90 |
| LEO Pharma Inc. | 3 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Aimmune Therapeutics, Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 3 | $46 |
| Blueprint Medicines Corporation | 1 | $42 |
| Covis Pharma GmbH | 2 | $37 |
| Biocryst US Sales Co., LLC | 1 | $28 |
| Alk-abello, Inc | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $21 |
| USWM, LLC | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| Phadia US Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$342
How this compares
$9,291 in reported general payments places this provider in the 70th percentile of 20 allergy & immunology providers in District of Columbia.
See all allergy & immunology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 201 | $150,034 |
| Dupixent PenDupilumab | 24 | $98,317 |
| Arnuity ElliptaFluticasone Furoate | 66 | $19,211 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $18,549 |
| Spiriva RespimatTiotropium Bromide | 11 | $11,812 |
| DuleraMometasone/Formoterol | 28 | $10,908 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $10,762 |
| Qvar RedihalerBeclomethasone Dipropionate | 25 | $9,920 |
| XhanceFluticasone Propionate | 12 | $7,376 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 49 | $6,458 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $4,150 |
| Montelukast Sodium | 243 | $3,958 |
| Azelastine Hcl | 109 | $3,574 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 96 | $3,324 |
| Epinephrine | 18 | $3,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $1,074 | $187,794298 claims |
| Boehringer IngelheimSpiriva Respimat | $206 | $11,81211 claims |
| AstraZenecaBreztri Aerosphere | $2,724 | $10,76214 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $46 | $9,92025 claims |
| Optinose US, Inc.Xhance | $355 | $7,37612 claims |
| Hikma Pharmaceuticals USAEpinephrine | $134 | $3,29318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 20 allergy & immunology providers in District of Columbia.
Other allergy & immunology in Washington
- Autumn BurnetteWashington$2.3M
- Lawrence DubuskeWashington$1.8M
- Eliane Abou-JaoudeWashington$66K
- Daniel EinWashington$52K
- Olabunmi AgboolaWashington$13K
- Michael KellerWashington$9K
- Maribel Mamonluk-ChuaWashington$7K
- Sebastian Ochoa GonzalezWashington$6K
- Janine van LanckerWashington$4K
- Sana HabibWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.